Acute myelogenous leukemia (AML) stem cell subpopulations, known as CD34+/CD- cells, were also shown to have high expression levels of the breast cancer resistance protein (BCRP-ABCG2 protein), which was initiated to be actively implicated in drug efflux [9]. The gene discussed is CD34; the disease is acute myeloid leukemia.